Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Background: Base excision repair (BER) plays an important role in the maintenance of genome integrity and anticancer drug resistance. This study aimed to explore the role of BER gene polymorphisms in response to chemotherapy for advanced non-small cell lung cancer (NSCLC) patients treated with plati...

Full description

Bibliographic Details
Main Authors: Jie Dong, Xu Wang, Yu Yu, Xu Yan, Jiu-Wei Cui
Format: Article
Language:English
Published: Wolters Kluwer 2018-01-01
Series:Chinese Medical Journal
Subjects:
Online Access:http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=16;spage=1904;epage=1908;aulast=Dong
_version_ 1819107087813181440
author Jie Dong
Xu Wang
Yu Yu
Xu Yan
Jiu-Wei Cui
author_facet Jie Dong
Xu Wang
Yu Yu
Xu Yan
Jiu-Wei Cui
author_sort Jie Dong
collection DOAJ
description Background: Base excision repair (BER) plays an important role in the maintenance of genome integrity and anticancer drug resistance. This study aimed to explore the role of BER gene polymorphisms in response to chemotherapy for advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Methods: During the period from November 2009 to January 2016, a total of 152 patients diagnosed with NSCLC Stage IIIB and IV in the First Hospital of Jilin University were admitted into this study. The XRCC1 G28152A, MUTYH G972C, HOGG1 C1245G, and PARP1 T2444C polymorphisms of all the patients were detected by mass spectrometry. The logistic regression was used for statictical analysis. All tests were bilateral test, and a P < 0.05 was considered statistically significant. Results: The logistic regression model showed that the response rate of chemotherapy of the PARP1 T2444C polymorphisms, CC genotype (odds ratio [OR]: 5.216, 95% confidence interval [CI]: 1.568–17.352, P = 0.007), TC genotype (OR: 2.692, 95% CI: 1.007–7.198, P = 0.048), as well as the genotype of TC together with CC (OR: 3.178, 95% CI: 1.229–8.219, P = 0.017) were significantly higher than those of TT wild type. There was no relationship between the MUTYH G972C, XRCC1 G28152A, and HOGG1 C1245G gene polymorphisms and chemosensitivity. Conclusions: The PARP1 2444 mutation allele C might be associated with the decreased sensitivity to platinum-based chemotherapy in advanced NSCLC. These findings may be helpful in designing individualized cancer treatment.
first_indexed 2024-12-22T02:48:28Z
format Article
id doaj.art-0e06a49cc91f45859559d5be8799ad2f
institution Directory Open Access Journal
issn 0366-6999
language English
last_indexed 2024-12-22T02:48:28Z
publishDate 2018-01-01
publisher Wolters Kluwer
record_format Article
series Chinese Medical Journal
spelling doaj.art-0e06a49cc91f45859559d5be8799ad2f2022-12-21T18:41:27ZengWolters KluwerChinese Medical Journal0366-69992018-01-01131161904190810.4103/0366-6999.238141Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung CancerJie DongXu WangYu YuXu YanJiu-Wei CuiBackground: Base excision repair (BER) plays an important role in the maintenance of genome integrity and anticancer drug resistance. This study aimed to explore the role of BER gene polymorphisms in response to chemotherapy for advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Methods: During the period from November 2009 to January 2016, a total of 152 patients diagnosed with NSCLC Stage IIIB and IV in the First Hospital of Jilin University were admitted into this study. The XRCC1 G28152A, MUTYH G972C, HOGG1 C1245G, and PARP1 T2444C polymorphisms of all the patients were detected by mass spectrometry. The logistic regression was used for statictical analysis. All tests were bilateral test, and a P < 0.05 was considered statistically significant. Results: The logistic regression model showed that the response rate of chemotherapy of the PARP1 T2444C polymorphisms, CC genotype (odds ratio [OR]: 5.216, 95% confidence interval [CI]: 1.568–17.352, P = 0.007), TC genotype (OR: 2.692, 95% CI: 1.007–7.198, P = 0.048), as well as the genotype of TC together with CC (OR: 3.178, 95% CI: 1.229–8.219, P = 0.017) were significantly higher than those of TT wild type. There was no relationship between the MUTYH G972C, XRCC1 G28152A, and HOGG1 C1245G gene polymorphisms and chemosensitivity. Conclusions: The PARP1 2444 mutation allele C might be associated with the decreased sensitivity to platinum-based chemotherapy in advanced NSCLC. These findings may be helpful in designing individualized cancer treatment.http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=16;spage=1904;epage=1908;aulast=DongBase Excision Repair; Chemotherapy; DNA Repair; Genetic; Non-Small Cell Lung Cancer; Platinum; Polymorphism
spellingShingle Jie Dong
Xu Wang
Yu Yu
Xu Yan
Jiu-Wei Cui
Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
Chinese Medical Journal
Base Excision Repair; Chemotherapy; DNA Repair; Genetic; Non-Small Cell Lung Cancer; Platinum; Polymorphism
title Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
title_full Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
title_fullStr Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
title_full_unstemmed Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
title_short Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer
title_sort association of base excision repair gene polymorphisms with the response to chemotherapy in advanced non small cell lung cancer
topic Base Excision Repair; Chemotherapy; DNA Repair; Genetic; Non-Small Cell Lung Cancer; Platinum; Polymorphism
url http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=16;spage=1904;epage=1908;aulast=Dong
work_keys_str_mv AT jiedong associationofbaseexcisionrepairgenepolymorphismswiththeresponsetochemotherapyinadvancednonsmallcelllungcancer
AT xuwang associationofbaseexcisionrepairgenepolymorphismswiththeresponsetochemotherapyinadvancednonsmallcelllungcancer
AT yuyu associationofbaseexcisionrepairgenepolymorphismswiththeresponsetochemotherapyinadvancednonsmallcelllungcancer
AT xuyan associationofbaseexcisionrepairgenepolymorphismswiththeresponsetochemotherapyinadvancednonsmallcelllungcancer
AT jiuweicui associationofbaseexcisionrepairgenepolymorphismswiththeresponsetochemotherapyinadvancednonsmallcelllungcancer